Viking Q1 2022 net loss $16.1M; VK2809 enrollment continues, VK2735 Phase 1 ongoing

Viking Therapeutics, Inc.

2023-Q1 EPS reported -$0.21

Net loss $16.1M ($0.21/share) vs $14.0M ($0.19/share) in Q1 2021; R&D up to $12.6M.
Cash and investments $184.9M at March 31, 2022, down from $202.1M at Dec 31, 2021.
Phase 2b VOYAGE study of VK2809 for NASH expects to complete enrollment in 2H22.
Phase 1 trial of dual GLP-1/GIP agonist VK2735 ongoing; results expected by year-end.
VK0214 for X-ALD on clinical hold, expects to submit requested preclinical data to FDA in 2Q22.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.